Cure8 trial brief
Dietary components and processed vegetarian/vegan products may alter the gut microbiome and intestinal barrier — both are relevant to IBD. This study will directly compare common vegan products and meat substitutes with traditional dairy- and meat-based diets in healthy people and people with IBD.
Patients with Crohn's disease or ulcerative colitis, clinicians (gastroenterologists, dietitians), and researchers interested in diet–microbiome interactions
This is a clinicaltrials.gov record for a recruiting interventional study (Region Skåne) testing how consuming fermented vegan-style vs dairy yogurt, and vegetarian meat substitutes vs regular meat, affects gut microbiota and gut barrier integrity in healthy volunteers and people with inflammatory bowel disease (ulcerative colitis and Crohn's disease).
Participants provide fecal samples and blood tests; microbiota will be analyzed by next-generation sequencing and qPCR, and barrier integrity estimated by bacterial DNA in blood and (in some cases) live bacteria. The study is non-randomized and prospective; participants act as their own controls and interventions last about four weeks per comparison.
IBD patients will have disease activity monitored with clinical scores and routine blood tests as part of follow-up.
This is a registered interventional trial (clinicaltrials.gov) that describes planned measurements (microbiome sequencing, qPCR, blood bacterial DNA) and short dietary exposure periods. It does not present results and has a non-randomized design; interpret any future findings with those limitations in mind.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.
